1 Shen, C. et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA, doi:10.1001/jama.2020.4783 (2020).
2 Li, L. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA, doi:10.1001/jama.2020.10044 (2020).
3 Salazar, E. et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol 190, 1680-1690, doi:10.1016/j.ajpath.2020.05.014 (2020).
4 Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864-1868, doi:10.1126/science.1116480 (2005).
5 Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol 3, 237-261, doi:10.1146/annurev-virology-110615-042301 (2016).
6 Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221-224, doi:10.1038/s41586-020-2179-y (2020).
7 Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17, 613-620, doi:10.1038/s41423-020-0400-4 (2020).
8 Zhang, L. et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv, doi:10.1101/2020.06.12.148726 (2020).
9 Korber, B. et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv (2020).
10 Li, Q. et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell, doi:10.1016/j.cell.2020.07.012 (2020).
11 Quinlan, B. D. et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. bioRxiv, doi:https://doi.org/10.1101/2020.04.10.036418 (2020).
12 Ou, J. et al. Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein. bioRxiv, doi:https://doi.org/10.1101/2020.03.15.991844 (2020).
13 Nelson-Sathi, S. et al. Structural and Functional Implications of Non-synonymous Mutations in the Spike protein of 2,954 SARS-CoV-2 Genomes. bioRxiv, doi:https://doi.org/10.1101/2020.05.02.071811 (2020).
14 Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, doi:10.1126/science.abd0827 (2020).
15 Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, doi:10.1038/s41586-020-2380-z (2020).
16 Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, doi:10.1038/s41586-020-2381-y (2020).
17 Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278, doi:10.1126/science.abc2241 (2020).
18 Hurlburt, N. K. et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. bioRxiv, doi:https://doi.org/10.1101/2020.06.12.148692 (2020).
19 Yuan, M. et al. Structural basis of a public antibody response to SARS-CoV-2. bioRxiv, doi:10.1101/2020.06.08.141267 (2020).
20 Wang, Q. et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 181, 894-904 e899, doi:10.1016/j.cell.2020.03.045 (2020).
21 Yurkovetskiy, L. et al. SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain. bioRxiv, doi:10.1101/2020.07.04.187757 (2020).
22 Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science, doi:10.1126/science.abd2321 (2020).
23 Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263, doi:10.1126/science.abb2507 (2020).
24 Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).
25 Cleary, S. J. et al. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br J Pharmacol, doi:10.1111/bph.15143 (2020).
26 Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature, doi:10.1038/s41586-020-2312-y (2020).
27 Chan, J. F. et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis, doi:10.1093/cid/ciaa325 (2020).
28 Williamson, B. N. et al. Reinfection could not occur in SARS-2 CoV-2 infected rhesus macaques. bioRxiv, doi:https://doi.org/10.1101/2020.04.15.043166 (2020).
29 Deng, W. et al. Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route. bioRxiv, doi:https://doi.org/10.1101/2020.03.13.990036 (2020).
30 Kim, Y. I. et al. Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe 27, 704-709 e702, doi:10.1016/j.chom.2020.03.023 (2020).
31 Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834-838, doi:10.1038/s41586-020-2342-5 (2020).
32 Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature, doi:10.1038/s41586-020-2324-7 (2020).
33 Park, S. J. et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBio 11, doi:10.1128/mBio.01114-20 (2020).
34 Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J Virol 85, 10582-10597, doi:10.1128/JVI.00671-11 (2011).
35 Wang, Q. et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis 2, 361-376, doi:10.1021/acsinfecdis.6b00006 (2016).